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Five-Year Follow-Up After
Sirolimus-Eluting Stent Implantation
Results of the SIRIUS (Sirolimus-Eluting
Stent in De-Novo Native Coronary Lesions) Trial
Giora Weisz, MD,* Martin B. Leon, MD,* David R. Holmes, JR, MD,† Dean J. Kereiakes, MD,‡
Jeffrey J. Popma, MD,§ Paul S. Teirstein, MD, Sidney A. Cohen, MD, PHD,¶#
Hong Wang, MD, MPH,# Donald E. Cutlip, MD,** Jeffrey W. Moses, MD*
New York, New York; Rochester, Minnesota; Cincinnati, Ohio; Boston, Massachusetts; La Jolla, California;
Philadelphia, Pennsylvania; and Warren, New Jersey
Objectives The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the
SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial.
Background The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES)
significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared
with bare-metal stents (BMS).
Methods Patients (n  1,058) with de novo native coronary artery lesions were randomized to either SES (n  533) or
control BMS (n  525) and were followed for 5 years.
Results Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control
groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4% versus 24.2%
(p  0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3% versus 33.5%
and 22.5% versus 33.5%, respectively (p  0.0001 for both). There were no significant differences in death,
myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the
cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0%
vs. 0.8%) or Academic Research Consortium definitions (3.9% vs. 4.2%).
Conclusions In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES con-
tinue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death
and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or
late stent thrombosis. (J Am Coll Cardiol 2009;53:1488–97) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.050d
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rovement in angiographic outcomes, with reduced rates of
estenosis and need for revascularization compared with bare-
etal stent (BMS) controls (1–5). These favorable clinical
utcomes have resulted in the frequent use of drug-eluting
tents during percutaneous coronary revascularization proce-
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orld. However, reports of drug-eluting stent very late stent
hrombosis, associated with possible increased mortality, have
licited long-term safety concerns (6–11).
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April 28, 2009:1488–97 5-Year Follow-Up of the SIRIUS Trialrial examined the safety and efficacy of SES for up to 2
ears and indicated significant reduction in both restenosis
nd target lesion revascularization (TLR) (3–5). This report
xtends the clinical follow-up of the original SIRIUS patient
ohort to determine whether the early and midterm safety
nd efficacy of SES is maintained at 5 years.
ethods
tudy design and eligibility criteria. The methods of the
IRIUS trial were previously reported (3). Patients enrolled
n the study had a clinical history of angina and single
oronary target lesions, 15 to 30 mm in length, in vessels 2.5
o 3.5 mm in diameter.
ata collection and follow-up. Patients had clinical eval-
ations at 30 days and 6, 9, 12, 24, 36, 48, and 60 months.
he treatment identity (sirolimus or BMS) remained
linded throughout the follow-up period to both patients
nd investigators. Complete data compliance for all 5-year
ollow-up end points was 93.6% for the BMS group and
4.0% for the SES group.
tudy end points: repeat revascularization. This 5-year
ollow-up study focuses on late safety and effectiveness, namely
linical restenosis or TLR. This was defined as the need for
linically driven repeat revascularization of the target lesion. In
he absence of objective criteria for ischemia, an in-lesion
iameter stenosis by quantitative coronary angiography 70%
as also considered of sufficient severity to justify repeat
evascularization. The independent Clinical Events Commit-
ee blindly adjudicated all revascularization episodes.
ther secondary end points. SIRIUS secondary clinical
nd points included non-TLR target vessel revascularization
non-TLR TVR), target vessel failure (TVF), and major
dverse cardiac events (MACE). Non-TLR TVR was defined
s any clinically driven repeat percutaneous intervention of the
arget vessel or bypass surgery of the target vessel for a lesion
ther than the target lesion. A non–Q-wave myocardial in-
arction (MI) was defined as an increase in the creatine kinase
evel to more than twice the upper limit of the normal range
ccompanied by an increased level of creatine kinase-
yocardial band in the absence of new Q waves on the
lectrocardiogram. Cardiac death was defined as death due to
bvious cardiovascular events and procedure-related causes or
ny death in which a cardiac cause could not be excluded.
oncardiac death was defined as any death clearly not due to
ardiac causes (e.g., malignancy). A TVF was defined as any
VR (either target vessel coronary bypass surgery or target
essel percutaneous coronary intervention), MI (Q-wave or
on–Q-wave), or cardiac death that could not be clearly
ttributed to a vessel other than the target vessel. Major adverse
ardiac event was defined as a composite of death (cardiac and
oncardiac), MI (Q-wave or non–Q-wave), and any TLR
either target vessel coronary bypass surgery or target lesion
ercutaneous coronary intervention).
tent thrombosis. Early stent thrombosis, either acutewithin 24 h) or subacute (between 24 h and 30 days), was mefined according to protocol as
ngiographic documentation of
arget vessel occlusion or any death
r MI occurring within 30 days
hat was not clearly related to
auses other than stent occlusion.
he protocol definition of late
tent thrombosis was MI occur-
ing30 days after the index pro-
edure and attributable to the tar-
et vessel and angiographic
ocumentation (site-reported or
y quantitative coronary angio-
raphy) of thrombus or total
cclusion of the target site and
reedom from an interim revas-
ularization of the target vessel.
For the purposes of this re-
ort, we used both the protocol-derived and the recently
uggested Academic Research Consortium (ARC) (12)
efinitions of stent thrombosis. The ARC definitions con-
ider distinct reportable time points: acute stent thrombosis
0 to 24 h after stent implantation); subacute stent throm-
osis (24 h to 30 days); late stent thrombosis (30 days to
year); and very-late stent thrombosis (more than 1 year
fter stent implantation). The ARC definitions also recog-
ize 3 categories of evidence in defining stent thrombosis:
onfirmed/definite, probable, and possible. “Confirmed/
efinite” stent thrombosis was defined as an acute coronary
yndrome with symptoms, electrocardiogram changes, or
ore than 2-fold elevation in creatine phosphokinase com-
ined with either angiographic or pathologic confirmation
f stent thrombosis. “Probable” stent thrombosis was de-
ned as any unexplained death within the first 30 days or
rrespective of the time after the index procedure, or any MI
n the absence of an obvious cause that is related to docu-
ented acute ischemia in the territory (target vessel) of the
mplanted stent without angiographic confirmation of stent
hrombosis. “Possible” stent thrombosis was defined as any
nexplained death more than 30 days after the index proce-
ure. The ARC definitions did not censor stent thrombosis
vents that occurred after an intervening revascularization of
he target vessel.
tatistical analysis. Analyses were performed on a modi-
ed intent-to-treat population; deregistered patients were
ot included in the analysis, because they received neither
tudy treatment (3).
Continuous variables are summarized as mean  SD and
ere compared between treatment groups with the t test.
ategorical variables are summarized as frequencies and per-
entages and were compared between treatment groups with
he Fisher exact test. Differences and 95% confidence intervals
CIs) between the 2 comparison groups were also calculated.
vent-free incidence or cumulative incidences of selected
ong-term outcomes were summarized with the Kaplan-Meier
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
OR  odds ratio
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationethod and compared between treatment groups with log-
r
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s
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5-Year Follow-Up of the SIRIUS Trial April 28, 2009:1488–97ank tests. To identify the risk factors for the major long-term
utcomes, a series of univariate and multivariate predictor
nalyses were performed; multivariate predictors were chosen
ith an entry criterion of 0.20 and with a stay criterion of 0.10.
ll tests are 2-sided with a significant level of 0.05. All
Cumulative Clinical Events at 1- and 5-Year Clin
Table 1 Cumulative Clinical Events at 1- an
SES (n  533) B
All events at 1 yr
Death 7 (1.3)
Cardiac 3 (0.6)
Noncardiac 4 (0.8)
MI (all) 16 (3.0)
Q-wave 4 (0.8)
Non–Q-wave 12 (2.3)
Death or any MI 23 (4.3)
Death or Q-wave MI 11 (2.1)
TLR 26 (4.9)
TL CABG 5 (0.9)
TL PCI 23 (4.3)
All TVR 38 (7.1)
TVR (non-TL) 20 (3.8)
MACE 44 (8.3)
TVF 52 (9.8)
All events at 5 yrs
Death 45 (8.4)
Cardiac 22 (4.1)
Noncardiac 23 (4.3)
MI (all) 33 (6.2)
Q-wave 8 (1.5)
Non–Q-wave 26 (4.9)
Death or any MI 74 (13.9)
Death or Q-wave MI 51 (9.6)
TLR 50 (9.4)
TL CABG 12 (2.3)
TL PCI 43 (8.1)
All TVR 88 (16.5)
TVR (non-TL) 55 (10.3)
MACE 108 (20.3)
TVF 120 (22.5)
All events between 1 and 5 yrs
Death 38 (7.1)
Cardiac 19 (3.6)
Noncardiac 19 (3.6)
MI (all) 17 (3.2)
Q-wave 4 (0.8)
Non–Q-wave 14 (2.6)
Death or any MI 51 (9.6)
Death or Q-wave MI 40 (7.5)
TLR 24 (4.5)
TL CABG 7 (1.3)
TL PCI 20 (3.8)
All TVR 50 (9.4)
TVR (non-TL) 35 (6.6)
MACE 64 (12.0)
TVF 68 (12.8)
Values are number of cases (%). Events at 1 year were reported previ
BMS bare-metal stent(s); CABG coronary artery bypass graftMImyocardial infarction; PCI percutaneous coronary intervention; SES
revascularization; TVF target vessel failure; TVR target vessel revascularitatistical analyses were performed with SAS software (version
.2, SAS, Cary, North Carolina). The data were managed and
nalyzed exclusively by the Harvard Clinical Research Institute
uring the 5-year follow-up. The authors had full access to the
ata and take responsibility for its integrity.
ollow-Up
ear Clinical Follow-Up
 525) Difference (95% CI) p Value
0.8) 0.6% (0.7% to 1.8%) 0.55
0.4) 0.2% (0.6% to 1.0%) 1.00
0.4) 0.4% (0.5% to 1.3%) 0.69
4.2) 1.2% (3.4% to 1.1%) 0.33
0.8) 0.0% (1.1% to 1.0%) 1.00
3.4) 1.2% (3.2% to 0.8%) 0.27
4.8) 0.4% (3.0% to 2.1%) 0.77
1.5) 0.5% (1.1% to 2.1%) 0.64
20.2) 15.3% (19.2% to11.4%) 0.001
1.7) 0.8% (2.2% to 0.6%) 0.30
(19.2) 15.1% (18.9% to11.3%) 0.001
(22.9) 15.7% (19.9% to11.5%) 0.001
6.5) 2.7% (5.4% to0.1%) 0.05
(23.2) 15.0% (19.3% to10.7%) 0.001
(24.8) 15.0% (19.5% to10.5%) 0.001
8.4) 0.1% (3.3% to 3.4%) 1.00
3.6) 0.5% (1.8% to 2.8%) 0.75
4.8) 0.4% (3.0% to 2.1%) 0.77
(6.5) 0.3% (3.2% to 2.7%) 0.90
(1.1) 0.4% (1.0% to 1.7%) 0.79
(5.3) 0.5% (3.1% to 2.2%) 0.78
(13.3) 0.6% (3.6% to 4.7%) 0.86
(9.3) 0.2% (3.3% to 3.8%) 0.92
(24.2) 14.8% (19.2% to10.4%) 0.001
(3.4) 1.2% (3.2% to 0.8%) 0.27
(23.0) 15.0% (19.3% to10.7%) 0.001
(30.5) 14.0% (19.0% to8.9%) 0.001
(13.0) 2.6% (6.5% to 1.2%) 0.21
(33.5) 13.3% (18.5% to8.0%) 0.001
(34.7) 12.2% (17.6% to6.8%) 0.001
(7.6) 0.5% (3.6% to 2.7%) 0.81
(3.2) 0.3% (1.9% to 2.5%) 0.87
(4.4) 0.8% (3.2% to 1.5%) 0.53
(2.3) 0.9% (1.1% to 2.9%) 0.45
(0.4) 0.4% (0.5% to 1.3%) 0.69
(1.9) 0.7% (1.1% to 2.5%) 0.54
(8.6) 1.0% (2.5% to 4.5%) 0.59
(7.8) 0.3% (3.5% to 2.9%) 0.91
(4.0) 0.5% (1.9% to 2.9%) 0.76
(1.7) 0.4% (1.9% to 1.1%) 0.62
(3.6) 0.1% (2.1% to 2.4%) 1.00
(7.6) 1.8% (1.6% to 5.1%) 0.32
(6.5) 0.1% (2.9% to 3.1%) 1.00
(10.3) 1.7% (2.1% to 5.5%) 0.38
(9.9) 2.9% (1.0% to 6.7%) 0.15
).
; CI confidence interval; MACEmajor adverse cardiac event(s);ical F
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s previously reported, both groups had similar baseline
linical and angiographic characteristics, procedural factors,
nd acute (in-hospital) results (3).
Figure 1 Kaplan-Meier Event-Free Survival Curves
Kaplan-Meier event-free survival curves at 2 years for sirolimus-eluting stents (SES
Q-wave myocardial infarction (QMI); (B) target lesion revascularization (TLR) and ta
target vessel failure (TVF). The number of patients at risk each year is provided, e
minus those with earlier events. LR  log-rank test.evascularization and clinical events. After 5 years, the
ignificant differences between the SES and BMS groups in TLR,
VR, TVF, and MACE were all maintained (Table 1, Fig. 1).
uring the follow-up from 1 to 5 years, in both groups there
ere similar increases in the rates of all clinical end points.
control stents (CS) for (A) death  any myocardial infarction (MI) and death 
ssel revascularization (TVR); and (C) major adverse cardiac events (MACE) and
the number of patients for whom follow-up data were available at each time) and
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5-Year Follow-Up of the SIRIUS Trial April 28, 2009:1488–97The comparison of survival curves in freedom from death
r MI showed no significant differences over the follow-up
eriod (Fig. 1A). The event-free curves of TLR, TVR,
ACE, and TVF stayed separated and parallel throughout
he extended follow-up after 1 year (Figs. 1B and 1C).
Various higher restenosis risk patient and lesion sub-
roups (including diabetes, left anterior descending coro-
ary artery lesion location, small vessel size, and long lesion
ength) were examined (Fig. 2). In all cases, the significant
eduction in TLR associated with SES compared with BMS
ontrols in these selected subgroups was maintained at 5
ears.
Multivariate analyses identified the following predictors of
LR: treatment with control stent (vs. SES; odds ratio [OR]:
.44, p  0.0001), diabetes mellitus (OR: 1.86, p  0.001),
rior coronary artery bypass graft surgery (OR: 1.78, p 0.04),
otal numbers of stent implanted (OR: 1.70/mm stent-length
ncrease, p  0.0001), left anterior descending coronary artery
vs. other locations; OR: 1.52, p  0.02), post-procedure
n-stent minimal luminal diameter (/mm, OR: 0.52, p 
.003), and age (/year, OR: 0.98, p  0.04).
Multivariate analyses identified the following independent
redictors of death and MI: age (OR: 1.05, p 0.0001), stent
ength (OR: 1.04, p  0.002), smoking during the last year
efore procedure (OR: 1.94, p  0.005), congestive heart
ailure (OR: 2.06, p 0.02), reference vessel diameter (OR:
.62, p  0.03), hypertension (OR: 1.55, p  0.047), prior
I (OR: 1.47, p  0.054), and post-procedure hospital
ength of stay (OR: 1.32, p  0.004).
Figure 2 Odds Ratios for Target Lesion Revascularization at 5
Values represent event rates (%) in each arm by subgroup. Bars represent odds ra
CI  confidence interval; CS  control stent; LAD  treatment of lesions in the letent thrombosis. Stent thrombosis episodes (according to
ither the protocol or ARC definitions) are reported as early
vents up to 30 days after the index procedure, late events
rom 30 days to 1 year, and very late events between 1 and
years for both the sirolimus-eluting and the control stent
atients (Table 2). Early stent thrombosis was rare, irre-
pective of the definition. In the late time period between 30
ays and 1 year after stent placement, with both types of
efinitions there were low rates of stent thrombosis with
ontrol stents and SES (0.6% vs. 0.2% with the protocol
efinition of stent thrombosis; 0.7% vs. 0.2% with the
definite” plus “probable” ARC definition). During the last
years of follow-up, the very late period (years 1 to 5), there
ere 3 events with the protocol definition of stent throm-
osis but none with control stents (p  0.16). With the
RC definitions of very late “definite” stent thrombosis,
here were 4 cases of “definite” stent thrombosis with SES
nd 2 with BMS (0.8% and 0.4%, p 0.57). There was only
case of “probable” very late stent thrombosis in the BMS
roup and none in the SES group and no significant
ifference in the rates of “possible” very late stent thrombo-
is between SES and BMS (2.6% vs. 2.3%, p  0.74).
After 5 years of follow-up (Table 2, Fig. 3), the overall
umulative incidence of protocol-defined stent thrombosis
as not significantly different between SES and BMS
atients (1.0% vs. 0.8%; p  0.75). With ARC definitions
ompared with protocol definitions of stent thrombosis,
here was an increase in the number of stent thrombosis
vents (to 41 from 9) due to a lack of censoring stent
for the Overall Population and by Subgroup
int estimates and 95% confidence intervals.
rior descending artery; SES  sirolimus-eluting stent.Years
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April 28, 2009:1488–97 5-Year Follow-Up of the SIRIUS Trialhromboses after repeat revascularization events and the
ore expansive categories of “probable” and especially
possible” late stent thrombosis. The “definite” category of
he ARC-defined stent thrombosis events added only 1 case
o each stent group compared with the protocol-based
efinition, but the “probable” category included 4 additional
ases (all BMS) and the “possible” category included 26
dditional cases (14 SES and 12 BMS). There were no
Figure 3 Kaplan-Meier Curves Representing the 5-Year
Cumulative Incidence Rates of Stent Thrombosis
Kaplan-Meier curves representing the 5-year cumulative incidence rates of
stent thrombosis (ST) (A) protocol-defined (B) with the Academic Research
Consortium (ARC) definition. The number of patients at risk each year is pro-
vided, equal to the number of patients for whom follow-up data were available
at each time minus those with earlier events. LR  log-rank test; other abbrevi-
ations as in Figure 2.significant differences between SES and BMS in the overallSt
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5-Year Follow-Up of the SIRIUS Trial April 28, 2009:1488–97requency of stent thrombosis with ARC definitions (cu-
ulative incidence SES 3.9% vs. BMS 4.2%; p  0.85).
iabetes mellitus. A total of 279 patients (26.4%) had
iabetes mellitus, and the baseline demographic data, lesion
haracteristics, and short-term outcomes of the diabetic
atients have been reported previously (13). The long-term
linical outcomes of the patients with diabetes mellitus are
ummarized in Table 3. Diabetic patients generally had
igher frequencies of clinical events compared with patients
ithout diabetes in each treatment group (Table 3). In SES
atients, diabetic patients had more frequent cardiac death
han nondiabetic patients (9.9% vs. 4.2%, p  0.0004) and
n BMS patients, diabetic patients had more frequent TLR
vents (33.1% vs. 20.7%, p  0.0045). When comparing
ES versus BMS at 5 years in both diabetic and nondiabetic
atients, there were significant reductions in the frequency
f TLR, TVR, MACE, and TVF, but no significant
ifferences were observed in the rates of death and MI. A
onsignificant increased rate of cardiac death with SES
ersus BMS in diabetic patients was observed (9.9% vs.
.7%; p  0.11). This was associated with a cluster of death
vents in the SES group in the first one-half of the third
ear after the index procedure (Fig. 4).
In the diabetic subgroup, there were no significant
ifferences in overall protocol-defined stent thrombosis after
ES treatment (SES: 2 events [1.6%] vs. BMS: 1 event
0.7%]; p  0.48), and there were also no significant
ifferences in ARC “definite” plus “probable” stent throm-
osis (SES: 3 events [2.6%] vs. BMS: 4 events [2.9%]; p 
.85). Due to the increased cardiac death events during
ollow-up in the diabetic SES patients, there was a trend
oward more frequent ARC “possible” stent thrombosis
SES: 9 events [7.5%] vs. BMS: 4 events [3.0%]; p  0.09).
he overall cumulative incidence of ARC-defined stent
hrombosis was 9.9% (12 events) in SES patients and 5.9%
8 events) in BMS patients (p  0.22).
The results related to the diabetic patients in the SIRIUS
rial should be interpreted with caution. The number of
iabetic patients in this study was small, and further studies
ocused on this group of patients are needed.
iscussion
he SIRIUS trial is the largest randomized study (n 
,058) of patients with symptomatic coronary disease com-
aring treatment of the culprit lesion with SES with the
redicate BMS (3). Eight-month angiographic follow-up in
03 patients and 9-month clinical follow-up in all patients
ndicated a marked reduction in late lumen loss (in-stent:
.00 mm vs. 0.17 mm, p  0.001), binary in-lesion
estenosis (36.3% vs. 8.9%, p  0.001), and clinically driven
LR (16.6% vs. 4.1%, p  0.001) when comparing control
MS with the SES. When clinical follow-up was extended
o 12 and 24 months, the improvement in clinical restenosis
clinically driven TLR) was maintained after SES treatment
4,5). On the basis of these angiographic and clinical Cu T
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April 28, 2009:1488–97 5-Year Follow-Up of the SIRIUS Trialutcomes from the SIRIUS trial, the Food and Drug
dministration approved the use of SES in April 2003.
The 5-year SIRIUS follow-up analysis shows no evidence
f disproportionate late clinical events with SES, including
eath, MI, stent thrombosis, and repeat revascularizations
Tables 1 and 2, Figs. 1 to 3). The major findings of this
-year follow-up report involving patients treated with SES
rom the SIRIUS trial are: 1) clinical restenosis (with
linded adjudication of all clinically driven TLR events)
hows maintained anti-restenosis efficacy; and 2) late com-
lications such as stent thrombosis, MI, and death between
and 5 years were uncommon and occurred with similar
requency in sirolimus and BMS groups.
On the basis of previous experience with potent antipro-
iferative strategies to prevent in-stent restenosis, such as
rachytherapy (14–16), concerns were expressed regarding
he long-term durability of the anti-restenosis efficacy asso-
iated with SES. The 5-year results from the SIRIUS trial
emonstrate that the significant differences in rates of
evascularization, both TLR and TVR, were maintained
ithout late catch-up phenomenon (Table 1, Fig. 1). With
ES, the need for revascularization between 1 and 5 years
as uncommon (TLR 1.1%; TVR 2.3%/year) and similar to
ontrol stents. At 5-year follow-up, the long-term clinically
riven TLR was still markedly reduced (by 61%) from
4.2% in the control group to 9.4% in SES-treated patients
p  0.001). Thus, by using an SES in the SIRIUS trial, at
years, 149 repeat revascularization events were prevented
or every 1,000 patients treated (Fig. 2). This demonstration
Figure 4 Kaplan-Meier Curves Representing the 5-Year Cumula
Kaplan-Meier curves representing the 5-year cumulative incidence rates of death f
provided, equal to the number of patients for whom follow-up data were availablef the potency and durability of the anti-restenosis effect of cES is clearly distinguished from previous strategies to
revent in-stent restenosis.
No important safety differences were observed comparing
ES versus control stents, examining the hard clinical end
oints of death (all and cardiac) and MI (all and Q-wave),
lone or in combination. The mean annual frequency (after
ear 1) was 1% for both cardiac death and MI. These
ong-term events are comparable to previously published
atural history reports in patients with coronary disease
reated with percutaneous coronary revascularization mo-
alities (17–19).
tent thrombosis. Stent thrombosis is a dramatic clinical
vent associated with MI and frequent mortality. Recent
ublications including long-term follow-up of randomized
rials and registries as well as some meta-analyses have
ndicated that drug-eluting stents (both SES and paclitaxel-
luting stents) might be associated with increased rates of
ery late stent thrombosis (after 1 year), compared with
MS (7,9,11,20–22). For patients similar to those enrolled
n the SIRIUS trial, the incremental very late stent throm-
osis event rates have been small, approximately 2 patients/
ear/1,000 patients treated. Therefore, rigorous late clinical
ollow-up of the blinded randomized trials using re-
djudicated standardized definitions becomes essential to
nsure patient safety. The SIRIUS trial’s 5-year follow-up
onfirms a low rate of very late stent thrombosis events
ssociated with SES and BMS (3 and 0 events, respectively;
 0.1556). However, after re-adjudicating all follow-up
vents with the ARC definitions, which both broadens the
ncidence Rates of Death for Patients With DM
ents with diabetes mellitus (DM). The number of patients at risk each year is
h time minus those with earlier events. Abbreviations as in Figures 2 and 3.tive I
or pati
at eaclassification of events captured as stent thrombosis and no
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5-Year Follow-Up of the SIRIUS Trial April 28, 2009:1488–97onger censors events after an intervening repeat revascular-
zation, the differences between SES and BMS are substan-
ially diminished (“definite” plus “probable”: 4 vs. 3 events,
espectively) (Table 2). The cumulative 5-year frequencies
f stent thrombosis—applying the ARC definitions—also
ndicated a similar occurrence of stent thrombosis in the
ES and BMS patients (“definite”: approximately 0.2%/
ear; and combined “definite,” “probable,” and “possible”:
pproximately 0.8%/year for both SES and BMS patients).
hus, in the SIRIUS patient population—constituting
hat is now considered “on-label” use—in a carefully
onducted, randomized, double-blind study with almost
omplete long-term follow-up, the use of SES did not lead
o an increase in stent thrombosis.
iabetes mellitus. Diabetes mellitus is a well-known risk
actor for increased restenosis and worse prognosis (death
nd MI) in patients with coronary artery disease treated
ith percutaneous transcatheter interventions (23–26).
uring follow-up, the diabetic patients enrolled in SIRIUS
ad more repeat revascularization events than the non-
iabetic patients, in both the SES and BMS treatment
roups (Table 3). The time course of restenosis seemed
naltered, with the vast majority of events occurring in the
rst year. Importantly, despite an absolute increase in the
requency of events, the relative antirestenosis efficacy of
ES was similar in diabetic versus nondiabetic patients
TLR decrease by SES was 59% in diabetic patients and
1% in nondiabetic patients, and the actual number of TLR
vents prevented/1,000 patients treated was actually greater
n diabetic patients than in nondiabetic patients.
A recent pooled analysis raised concerns that SES might
dversely affect mortality in patients with diabetes (27). This
ooled analysis examined the 4-year outcomes from 4
linded, randomized studies comparing SES with BMS,
ncluding the SIRIUS trial, which comprised 65% of the
verall patient cohort. There were significant differences in
ong-term mortality that might be explained by an unex-
ectedly low frequency of deaths in the diabetic control
tent population. In the SIRIUS 5-year follow-up analysis,
here is a statistically nonsignificant higher overall noncar-
iac mortality in diabetic patients treated with SES versus
MS (overall mortality: 15.3% vs. 9.5%, difference 5.8%,
5% CI: 1.9% to 13.6%; and cardiac mortality: 9.9% vs.
.7%, difference 5.2%, 95% CI: 1.0% to 11.4%). The
ortality differences were largely the result of a cluster of
ardiac death events occurring in the first portion of year 3
Fig. 4). Once again, there was an unexpectedly low fre-
uency of cardiac deaths in diabetic BMS patients (1%/
ear), which contributed to the apparent differences.
ollow-up from dedicated randomized trials in diabetic
atients and large registries is ongoing and should further
larify this hypothesis-generating observation.
Diabetes has previously been reported as a predictor for
tent thrombosis in drug-eluting stent clinical studies (6–
,21). In the SIRIUS trial, the overall 5-year stent throm-
osis frequencies (both protocol-defined and ARC “defi-ite” and “probable”) were not different in diabetic patients
ompared with nondiabetic patients and uninfluenced by
ES versus BMS treatment. Due to the aforementioned
nexplained late increase in cardiac deaths with SES in
iabetic patients, there was a likewise statistically nonsig-
ificant increase in 5-year ARC “possible” stent thrombosis
vents (SES vs. CS: 9.9% vs. 5.9%, p  0.22).
tudy limitations. The SIRIUS trial was the first large
andomized trial evaluating the clinical outcomes of a new
rug-eluting stent compared with a blinded BMS control.
s such, the patient population was restricted in complexity,
nd so-called “off label” anatomic categories that might
esult in higher clinical event rates were systematically
xcluded (6,7,28). The use of dual antiplatelet therapy
aspirin and clopidogrel) was only mandated by protocol for
months, and no long-term information on use of anti-
latelet agents was collected.
Diabetic patients were neither randomized nor stratified
or enrollment in this study; thus, evaluations of outcomes
n diabetic patients were not pre-specified and are post hoc
nalyses. Reported outcomes in diabetic patients are thus
ubject to the limitations of such an analysis.
onclusions
he 5-year follow-up of the double-blinded, randomized
IRIUS trial comparing SES with BMS confirms the
ong-term safety and efficacy of SES in patients with simple
nd medium complexity native coronary lesions. All anti-
estenosis efficacy parameters of reduced revascularization,
ll safety end points (death, MI, and stent thrombosis), and
omposite safety and efficacy end points (MACE and TVF)
uggested maintained benefit of SES in reducing subse-
uent revascularization events without adversely affecting
afety. Undoubtedly, because this study only represents a
lice of the patient population currently treated with SES,
dditional long-term follow-up studies are essential to
etermine the safety and efficacy of SES in more complex
atient groups and higher-risk anatomic subsets.
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